Olema Pharmaceuticals (OLMA) Net Cash Flow (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Net Cash Flow of $4.2 million for Q1 2026, up 104.78% year-over-year from $2.1 million in Q1 2025, and down 67.44% quarter-over-quarter from $13.0 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Net Cash Flow (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Net Cash Flow for 7 consecutive years, with $4.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 104.78% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $1.9 million (down 88.73% YoY), while the FY2025 annual figure was -$91.2 million, down 228.53% from the prior year.
- Net Cash Flow fell to $4.2 million in Q1 2026 per OLMA's latest filing, from $13.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $103.6 million in Q4 2024 and bottomed at -$88.8 million in Q1 2025.
- Historically, Net Cash Flow has averaged $2.3 million across 5 years, with a median of $2.3 million in 2022.
- On a YoY basis, Net Cash Flow climbed as much as 3519.36% in 2023 and fell as far as 1475.37% in 2023.
- Olema Pharmaceuticals' Net Cash Flow stood at -$3.1 million in 2022, then plunged by 1475.37% to -$48.9 million in 2023, then jumped by 311.98% to $103.6 million in 2024, then slumped by 87.41% to $13.0 million in 2025, then slumped by 67.44% to $4.2 million in 2026.
- Business Quant data shows OLMA's Net Cash Flow at $4.2 million in Q1 2026, $13.0 million in Q4 2025, and -$17.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | -3.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.95 Mn |
| Jun 30, 2026 | -3.95 Mn |
| Mar 31, 2026 | 4.25 Mn |
| Mar 31, 2026 | 4.25 Mn |
| Dec 31, 2025 | 13.04 Mn |
| Dec 31, 2025 | 13.04 Mn |
| Sep 30, 2025 | -17.21 Mn |
| Sep 30, 2025 | -17.21 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Mar 31, 2025 | -88.84 Mn |
| Mar 31, 2025 | -88.84 Mn |
| Dec 31, 2024 | 103.59 Mn |
| Dec 31, 2024 | 103.59 Mn |
| Sep 30, 2024 | 19.00 Mn |
| Sep 30, 2024 | 19.00 Mn |
| Jun 30, 2024 | -16.83 Mn |
| Jun 30, 2024 | -16.83 Mn |
| Mar 31, 2024 | -34.82 Mn |
| Mar 31, 2024 | -34.82 Mn |